New biobank aims to unlock better treatments for blood diseases
NCT ID NCT07227155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects blood samples and health information from 375 people with non-cancerous blood disorders like aplastic anemia, sickle cell disease, or thalassemia who are receiving a stem cell transplant or gene therapy. The goal is to create a biobank that helps researchers understand why these treatments sometimes fail and how to make them safer and more effective. Participants provide samples before and after treatment, but this study does not test a new therapy itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor College of Medicine
RECRUITINGHouston, Texas, 77030, United States
-
Children's Hospital of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Fred Hutchinson Cancer Center
NOT_YET_RECRUITINGSeattle, Washington, 98109, United States
-
Oregon Health and Science University
NOT_YET_RECRUITINGPortland, Oregon, 97239, United States
-
University of Florida
NOT_YET_RECRUITINGGainesville, Florida, 32611, United States
-
Vanderbilt University Medical Center
NOT_YET_RECRUITINGNashville, Tennessee, 37235, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Co-Designed support help parents embrace sickle cell care?
- Can community hospitals in zambia master severe disease care?
- A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
- Can a phone app keep teens on track with sickle cell treatment?
- A common amino acid may calm sickle cell pain crises — a trial puts it to the test
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease